Immunotherapy combo shows promise in colorectal cancer fight

NCT ID NCT06154538

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding an immune checkpoint inhibitor (a type of immunotherapy) to standard chemotherapy before surgery can improve outcomes for people with locally advanced colorectal cancer. About 170 participants will be randomly assigned to receive either the combination or chemotherapy alone. The main goal is to see if the combination leads to a higher rate of complete cancer disappearance in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immune checkpoint inhibitor (PD-1 antibody) plus FOLFOX chemotherapy
What this could lead to: If it works, this could lead to a more effective pre-surgery treatment that increases the chance of eliminating all cancer cells before surgery.
What could go wrong: This is an early phase 2 trial with only 170 participants, so results may not apply to everyone. Adding immunotherapy to chemo can also increase side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED COLORECTAL CARCINOMA

Contacts and locations

Locations

Cancer Hospital/ National Cancer Center, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100038, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, 250000, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.